Cargando…
Dasatinib-Induced Chylothorax Beyond 5 Years of Treatment: Is There Actually Any Limit?
Dasatinib is a tyrosine kinase inhibitor used for treatment of some specific types of leukaemia. The development of pleural effusion is a known adverse effect of dasatinib and chylothorax is exceptional. No case has been reported beyond 5 years of treatment and extensive search for an alternative di...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SMC Media Srl
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348434/ https://www.ncbi.nlm.nih.gov/pubmed/37455693 http://dx.doi.org/10.12890/2023_003921 |